What iShares Biotechnology ETF (IBB) Sold: Gilead Leads on Oct. 13

gurufocus.com · 2026-10-15

In Tuesday's session, one ETF was buying while 232 were selling, and iShares Biotechnology ETF (IBB) was firmly on the selling side. The fund, with $10.50 billi

TickrTrends take: The iShares Biotechnology ETF's sale of Gilead shares reflects ongoing portfolio adjustments within the biotech sector, which is relevant context for evaluating AMGN's current positioning. Given TickrTrends' overvalued assessment of AMGN, movements by major biotech-focused funds warrant attention, as they may indicate shifting sentiment across the Healthcare sector. Investors focused on valuation should monitor whether similar rebalancing activity occurs in other biotechnology holdings, as this could suggest broader reassessment of pricing in the space where AMGN competes.

Read the full story at gurufocus.com →